Scarica l'app Stockscreener
31.28
0.06%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AMPH Giù?
Forum
Previsione
Precedente Chiudi:
$31.30
Aprire:
$31.55
Volume 24 ore:
498.67K
Relative Volume:
0.96
Capitalizzazione di mercato:
$1.50B
Reddito:
$723.55M
Utile/perdita netta:
$157.72M
Rapporto P/E:
10.43
EPS:
3
Flusso di cassa netto:
$170.15M
1 W Prestazione:
+0.84%
1M Prestazione:
-13.18%
6M Prestazione:
-33.26%
1 anno Prestazione:
-38.97%
Intervallo 1D:
$30.96
$31.60
Intervallo di 1 settimana:
$30.34
$31.65
Portata 52W:
$30.34
$56.38
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Nome
Amphastar Pharmaceuticals Inc
Settore
Telefono
909-980-9484
Indirizzo
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Confronta AMPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
31.28 | 1.50B | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Iniziato | Wells Fargo | Equal Weight |
| 2024-03-05 | Iniziato | JP Morgan | Overweight |
| 2023-11-17 | Iniziato | BofA Securities | Neutral |
| 2023-07-25 | Ripresa | Jefferies | Buy |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-07-29 | Iniziato | CapitalOne | Overweight |
| 2022-01-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Iniziato | Northland Capital | Outperform |
| 2019-03-13 | Downgrade | Needham | Buy → Hold |
| 2019-03-13 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-03-13 | Reiterato | Needham | Buy |
| 2017-12-01 | Reiterato | Needham | Buy |
| 2017-11-09 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Reiterato | Needham | Buy |
| 2017-03-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-05-10 | Reiterato | Needham | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2015-06-19 | Reiterato | Needham | Buy |
| 2015-06-03 | Iniziato | Raymond James | Strong Buy |
| 2014-07-21 | Iniziato | Needham | Buy |
Mostra tutto
Amphastar Pharmaceuticals Inc Borsa (AMPH) Ultime notizie
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update - MarketBeat
Can Amphastar's High-Value Pipeline Strategy Show Results? Q4 Earnings Preview - StockTitan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month LowHere's Why - MarketBeat
Amphastar Pharmaceuticals: A Gradual Strategy (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference - ACCESS Newswire
Amphastar Pharmaceuticals (AMPH) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Dextrose Injection Market: Demand, Growth, and Innovations 2025-2032 | Pfizer Inc., Amphastar Pharmaceuticals Inc - openPR
Yousif Capital Management LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
How the (AMPH) price action is used to our Advantage - Stock Traders Daily
State of Alaska Department of Revenue Sells 342 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Polaris Capital Management LLC Buys Shares of 24,500 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks - The Globe and Mail
Amphastar stock hits 52-week low at $31.54 amid market challenges - Investing.com Canada
Amphastar stock hits 52-week low at $34.08 amid market challenges - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Simply Wall St
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap DownShould You Sell? - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by Piper Sandler - MarketBeat
Boston Trust Walden Corp Purchases 439,281 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week LowHere's Why - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to Neutral - Defense World
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Sees Large Growth in Short Interest - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Piper Sandler cuts Amphastar stock rating, slashes price target By Investing.com - Investing.com Canada
Market Resilience: Amphastar Pharmaceuticals Inc (AMPH) Finishes Weak at 33.39, Down -4.24 - The Dwinnex
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66 - Marketscreener.com
Piper Sandler cuts Amphastar stock rating, slashes price target - MSN
Long Term Trading Analysis for (AMPH) - Stock Traders Daily
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46 -February 03, 2025 at 10:16 am EST - Marketscreener.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Amphastar Pharmaceuticals is Now Oversold (AMPH) - Nasdaq
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 - ACCESS Newswire
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 - ACCESS Newswire
Amphastar Receives FDA Approval for Vasopressin - ACCESS Newswire
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023 - ACCESS Newswire
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program - ACCESS Newswire
(AMPH) Technical Data - Stock Traders Daily
Amphastar Receives FDA Approval for Ganirelix Acetate Injection - ACCESS Newswire
Possible Bearish Signals With Amphastar Pharmaceuticals Insiders Disposing Stock - Simply Wall St
Amphastar Pharmaceuticals Inc Azioni (AMPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amphastar Pharmaceuticals Inc Azioni (AMPH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Option Exercise |
11.33 |
7,000 |
79,310 |
125,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 13 '24 |
Sale |
45.23 |
8,000 |
361,840 |
118,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Sale |
44.42 |
7,000 |
310,975 |
118,469 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Option Exercise |
19.52 |
10,000 |
195,200 |
40,471 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Sale |
43.77 |
10,000 |
437,702 |
30,471 |
3.23%
3.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):